1900 Wealth Management LLC Sells 1,595 Shares of Pfizer Inc. $PFE

1900 Wealth Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 7.3% during the second quarter, HoldingsChannel.com reports. The fund owned 20,296 shares of the biopharmaceutical company’s stock after selling 1,595 shares during the quarter. 1900 Wealth Management LLC’s holdings in Pfizer were worth $492,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter valued at $27,000. North Capital Inc. bought a new stake in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter valued at $28,000. Horizon Financial Services LLC bought a new stake in Pfizer during the first quarter valued at $35,000. Finally, WPG Advisers LLC bought a new stake in Pfizer during the first quarter valued at $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.5%

PFE opened at $27.08 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The firm has a market capitalization of $153.94 billion, a PE ratio of 14.40, a P/E/G ratio of 0.88 and a beta of 0.55. The company’s 50-day moving average is $24.62 and its 200 day moving average is $24.14.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PFE. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.29.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.